NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球膀胱癌市場預測(2021-2027)

Bladder Cancer Market 2021-2027

出版商 Orion Market Research Pvt Ltd 商品編碼 1025417
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
全球膀胱癌市場預測(2021-2027) Bladder Cancer Market 2021-2027
出版日期: 2021年07月10日內容資訊: 英文
簡介

在預測期內(2021-2027 年),全球膀胱癌市場預計將以 5.2% 的顯著複合年增長率增長。市場增長的主要驅動因素是煙草攝入、酒精消費、吸煙增加、寄生蟲感染、與膀胱癌相關的基因的特定變化,以及過去由於放射治療導致膀胱癌的治療。推動市場增長的關鍵因素包括藥物創新和開發,以及免疫療法和化學療法等各種療法的技術擴張。免疫療法等治療方法的進步和膀胱癌的增加預計將為膀胱癌市場提供增長機會。此外,政府研究、創新醫療設施和不斷增加的老年人口正在推動市場增長。然而,治療和診斷的高成本阻礙了市場的增長。

自 2019 年 12 月以來,COVID-19 大流行一直在影響全球的醫療保健服務。 COVID-19 大流行影響了泌尿腫瘤學的腫瘤學方法,並導致膀胱癌的手術治療延遲。此外,這種大流行對先前治療過的膀胱癌的新診斷和監測都有負面影響。此外,由於 COVID-19 的流行,卡介苗在世界範圍內未進行膀胱內註射,也沒有為高危非肌層浸潤□□性膀胱癌患者提供最佳治療。

本報告調查和分析全球膀胱癌市場,並提供有關市場概況、市場決定因素、細分市場、競爭條件、區域分析、主要公司等的系統信息。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和最新市場趨勢
  • 監管

第三章競爭形勢

主要公司分析

    • 概述
    • 財務分析
    • SWOT 分析
  • 主要戰略分析
  • COVID-19 對大公司的影響

第 4 章市場決定因素

  • 增長因素
  • 抑製器
  • 市場機會

第 5 章市場細分

  • 按癌症類型劃分的全球膀胱癌市場
    • 移行細胞癌/尿路上皮癌
    • 鱗狀上皮癌
    • 腺癌
    • 其他罕見類型(肉瘤、原位癌)
  • 按診斷方法劃分的全球膀胱癌市場
    • 膀胱鏡檢查
    • 活檢
    • 尿液分析
    • 尿液細胞病理學
    • 靜脈腎盂造影 (IVP)
    • 其他
  • 按治療分列的全球膀胱癌市場
    • 化療
    • 免疫療法
    • 放射治療
    • 手術
    • 其他

第六章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他領域

第 7 章公司簡介

  • AstraZeneca PLC
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Eli Lilly And Co.
  • Endo International Plc
  • Epocrates, Inc.
  • GlaxoSmithKline Plc
  • Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis International AG
  • Nucleix Ltd.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
目錄
Product Code: OMR2023846

Full-title:Global Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, Other Rare Types (Sarcomas, Carcinoma In Situ)), by Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), Other), by Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, other) type Forecast Period (2021-2027).

The global bladder cancer market is anticipated to grow at a considerable CAGR of 5.2% during the forecast period (2021-2027). The key factors that impel the growth of the market include the rising intake of tobacco, consumption of alcohol, and smoking, parasitic infections, and certain changes in the genes that are linked to bladder cancer, and Past treatment with radiation therapy that caused bladder cancer. The major factors that boost the growth of the market are included innovation and development in drugs and technological expansion in different therapies such as immunotherapy and chemotherapy. The advancement in treatment therapy such as immunotherapy and the increasing prevalence of bladder cancer is projected to create opportunities for the bladder cancer market. Additionally, government research, and innovative health care facilities, and an increasing geriatric population are boosting the growth of the market. The high costs of treatments and diagnosis are hindering the growth of the market.

The global bladder cancer market is hardly hit by the COVID-19 pandemic. The COVID-19 pandemic has affected healthcare services across the globe since December 2019. The covid-19 pandemic affected the oncological approaches in uro-oncology and cause to delay of surgical treatment for bladder cancer. Additionally, the pandemic has a negative impact on both new diagnoses, and surveillance of previously treated bladder cancer. The intravesical BCG treatment has not been performed across the globe due to the COVID-19 pandemic and caused suboptimal treatment for patients with high-risk non-muscle-invasive bladder cancer.

The global bladder cancer market is segmented based on cancer type, diagnosis method, therapy based on cancer type, the global bladder cancer market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, other rare types (sarcomas, carcinoma in situ). Based on the diagnosis method, the global bladder cancer market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), others. Based on the therapy, the global bladder cancer market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, others.

The global bladder cancer market is evaluated based on the geographical regions that are contributing considerable growth to the bladder cancer market. Based on geography North America held a significant share in 2020 in the market. The major factors that boost the market in the region included high healthcare expenditure, the substantial prevalence of bladder cancer with the surging geriatric population, and the presence of major market players in the region.  This is estimated to promote the growth of the market in the given forecast period. Additionally, Europe is expected to follow North America in terms of share occupied over the forecast period. This can be attributed to the increasing cases of bladder cancer in the region. The key market players in the market include AstraZeneca PLC, Celgene Corporation, Eli Lilly and Co, and Epocrates, Inc. among various others. Asia-Pacific region is expected to grow at the fastest rate as compared to all other regions over the forecast period.

Research Methodology

The market study of the global bladder cancer market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Bladder Cancer Market Research and Analysis by Cancer type
  • Global Bladder Cancer Market Research and Analysis by Diagnosis Method
  • Global Bladder Cancer Market Research and Analysis by Therapy

The Report Covers

  • Comprehensive research methodology of the global bladder cancer market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Global Bladder Cancer market.
  • Insights about market determinants that are stimulating the global bladder cancer market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

Key Company Analysis

    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Bladder Cancer Market, By Cancer Type
    • 5.1.1. Transitional Cell Bladder Cancer/ Urothelial Carcinoma
    • 5.1.2. Squamous Cell Bladder Cancer
    • 5.1.3. Adenocarcinoma
    • 5.1.4. Other Rare Types (Sarcomas, Carcinoma in Situ)
  • 5.2. Global Bladder Cancer Market, By Diagnosis Method
    • 5.2.1. Cystoscopy
    • 5.2.2. Biopsy
    • 5.2.3. Urinalysis
    • 5.2.4. Urine Cytology
    • 5.2.5. Intravenous Pyelogram (IVP)
    • 5.2.6. Other
  • 5.3. Global Bladder Cancer Market, By Therapy
    • 5.3.1. Chemotherapy
    • 5.3.2. Immunotherapy
    • 5.3.3. Radiation Therapy
    • 5.3.4. Surgery
    • 5.3.5. Other

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profile

  • 7.1. AstraZeneca PLC
  • 7.2. Bristol-Myers Squibb Co.
  • 7.3. Celgene Corp.
  • 7.4. Eli Lilly And Co.
  • 7.5. Endo International Plc
  • 7.6. Epocrates, Inc.
  • 7.7. GlaxoSmithKline Plc
  • 7.8. Hoffmann-La Roche Ltd.
  • 7.9. Johnson & Johnson Services, Inc.
  • 7.10. Merck & Co., Inc.
  • 7.11. Merck KGaA
  • 7.12. Novartis International AG
  • 7.13. Nucleix Ltd.
  • 7.14. Pfizer Inc.
  • 7.15. Spectrum Pharmaceuticals, Inc.

LIST OF TABLES

  • 1. GLOBAL BLADDER CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE 2020-2027 ($ MILLION)
  • 2. GLOBAL TRANSITIONAL CELL BLADDER CANCER/ UROTHELIAL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 3. GLOBAL TRANSITIONAL CELL BLADDER CANCER/ UROTHELIAL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 4. GLOBAL SQUAMOUS CELL BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 5. GLOBAL ADENOCARCINOMA MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 6. GLOBAL OTHER RARE TYPES (SARCOMAS, CARCINOMA IN SITU) MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 7. GLOBAL BLADDER CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2020-2027 ($ MILLION)
  • 8. GLOBAL CYSTOSCOPY FOR BLADDER CANCERMARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 9. GLOBAL BIOPSY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 10. GLOBAL URINALYSIS FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 11. GLOBAL URINE CYTOLOGY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 12. GLOBAL INTRAVENOUS PYELOGRAM (IVP) FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 13. GLOBAL OTHER DIAGNOSIS METHOD FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 14. GLOBAL BLADDER CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY 2020-2027 ($ MILLION)
  • 15. GLOBAL CHEMOTHERAPY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 16. GLOBAL IMMUNOTHERAPY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 17. GLOBAL RADIATION THERAPY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 18. GLOBAL SURGERY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
  • 19. GLOBAL OTHER THERAPY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)

20. NORTH AMERICA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)

21. NORTH AMERICA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD TYPE, 2020-2027 ($MILLION)

22. NORTH AMERICA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)

23. EUROPE BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)

24. EUROPE BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD TYPE, 2020-2027 ($MILLION)

25. EUROPE BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)

26. ASIA-PACIFIC BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)

27. ASIA-PACIFIC BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD TYPE, 2020-2027 ($MILLION)

28. ASIA-PACIFIC BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)

29. REST OF THE WORLD BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)

30. REST OF THE WORLD BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD TYPE, 2020-2027 ($MILLION)

31. REST OF THE WORLD BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL BLADDER CANCER MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL BLADDER CANCER MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL BLADDER CANCER MARKET, 2021-2027 (%)
  • 4. GLOBAL BLADDER CANCER MARKET BY CANCER TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL BLADDER CANCER MARKET BY DIAGNOSIS METHOD, 2020 VS 2027 (%)
  • 6. GLOBAL BLADDER CANCER MARKET BY THERAPY TYPE, 2020 VS 2027 (%)
  • 7. GLOBAL BLADDER CANCER MARKET BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL TRANSITIONAL CELL BLADDER CANCER/ UROTHELIAL CARCINOMA MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 9. GLOBAL TRANSITIONAL CELL BLADDER CANCER/ UROTHELIAL CARCINOMA MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 10. GLOBAL SQUAMOUS CELL BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 11. GLOBAL ADENOCARCINOMA MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 12. GLOBAL OTHER RARE TYPES (SARCOMAS, CARCINOMA IN SITU) MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 13. GLOBAL CYSTOSCOPY FOR BLADDER CANCERMARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 14. GLOBAL BIOPSY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 15. GLOBAL URINALYSIS FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 16. GLOBAL URINE CYTOLOGY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 17. GLOBAL INTRAVENOUS PYELOGRAM (IVP) FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 18. GLOBAL OTHER DIAGNOSIS METHOD FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 19. GLOBAL CHEMOTHERAPY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 20. GLOBAL IMMUNOTHERAPY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 21. GLOBAL RADIATION THERAPY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 22. GLOBAL SURGERY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 23. GLOBAL OTHER THERAPY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
  • 24. US BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. CANADA BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. UK BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. GERMANY BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. SPAIN BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. FRANCE BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. TALY BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. REST OF EUROPE BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. INDIA BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. CHINA BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 34. JAPAN BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 35. REST OF ASIA-PACIFIC BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 36. REST OF THE WORLD BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)